Yoshida O, Miyakawa M, Watanabe H, Mishina T, Kobayashi T, Nakagawa K, Fukuyama T, Ogura K, Ueyama H, Itoh H
Hinyokika Kiyo. 1983 Mar;29(3):357-64.
The effect of instillation therapy using CA alone or in combination with MMC, NCS or CQ was examined in 111 patients (92 males and 19 females, aged 32-87 years old with an average age of 66 years) with multiple superficial bladder tumors. The response rate of 29 patients given CA 400 mg alone was 48.3%, that of 25 patients given combination therapy of CA 200 mg and MMC 20 mg was 84.0%, that of 28 patients given combination therapy of CA 200 mg and NCS 4,000 U was 71.4%, that of 22 patients given combination therapy of CA 200 mg and NCS 6,000 U was 95.5% and that of 7 patients given combination therapy of CA 200 mg and CQ 10 mg was 100%. The response rates of the patients given any of the combination therapies were higher than that of the patients given CA alone. But because MMC, NCS and CQ were not administered singly, combination therapy cannot be concluded to be superior to single therapy. There was little difference between the response rate of primary cases and that of follow up cases. The side effects were all symptoms of local irritation, and were not indicative of systemic damage. Side effects were seen in 3.4%, 71.4%, 40.0% and 3.6% of the patients given CA alone, CA + CQ combination therapy, CA + MMC combination therapy and CA + NCS (4,000) therapy, respectively, combination therapy of CA and CQ producing the highest percentage of side effects.
对111例（92例男性，19例女性，年龄32 - 87岁，平均年龄66岁）多发浅表性膀胱肿瘤患者，研究了单独使用CA或CA联合MMC、NCS或CQ的灌注治疗效果。单独给予400mg CA的29例患者的缓解率为48.3%，给予200mg CA与20mg MMC联合治疗的25例患者的缓解率为84.0%，给予200mg CA与4000U NCS联合治疗的28例患者的缓解率为71.4%，给予200mg CA与6000U NCS联合治疗的22例患者的缓解率为95.5%，给予200mg CA与10mg CQ联合治疗的7例患者的缓解率为100%。接受任何联合治疗的患者的缓解率均高于单独给予CA的患者。但由于MMC、NCS和CQ未单独给药，不能得出联合治疗优于单一治疗的结论。原发病例和随访病例的缓解率差异不大。副作用均为局部刺激症状，未提示全身损害。单独给予CA、CA + CQ联合治疗、CA + MMC联合治疗和CA + NCS（4000）治疗的患者中，副作用发生率分别为3.4%、71.4%、40.0%和3.6%，CA与CQ联合治疗产生的副作用百分比最高。
